UK markets close in 5 hours 56 minutes

iShares $ Corp Bond ETF USD Dist (LQDA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
13.58-0.10 (-0.73%)
At close: 04:00PM EDT
13.59 +0.01 (+0.07%)
After hours: 04:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.68
Open14.03
Bid13.55 x 300
Ask13.62 x 600
Day's range13.48 - 13.92
52-week range5.71 - 16.99
Volume477,632
Avg. volume907,296
Market cap1.032B
Beta (5Y monthly)0.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference

    MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, beginning at 1:30 p.m. Eastern Time. Access to a webcast will be availa

  • GlobeNewswire

    Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

    On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed by United Therapeutics against the FDAOn March 31, regulatory exclusivity expired for Tyvaso® in treating PH-ILD MORRISVILLE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on Mar

  • GlobeNewswire

    Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

    Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalidAdvancing industry leading portfolio for inhaled treprostinil with YUTREPIA and sustained-release program L606Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial